Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2012

View Archived Issues

Proof-of-concept study begins with gevokizumab in acute coronary syndrome

InSite Vision completes enrollment in phase III BromSite study

Japanese group divulges new antibacterial agents

New hPASK/CK II inhibitors synthesized by Bioenergenix

Researchers at Novartis synthesize new CYP17 inhibitors

New TGR5 receptor agonists prepared by Bristol-Myers Squibb

GDC-0449 evaluated for new indication

Actinium Pharmaceuticals and Philogen begin development of Ac-225 labeled antibody

OPKO Health receives research grants from Mexican government

Priority review awarded for Eisai's NDA for new formulation of AcipHex

Taisho and Novartis sign agreement for diabetes treatment candidate in Japan

Viralytics reports preliminary data from research conducted with University of Surrey

Roche patents novel D3/5-HT2A receptor ligands

University of Sydney discloses novel agents isolated from propolis

New targets identified for malignant peripheral nerve sheath tumors

VR Laboratories selects new rhinovirus therapeutic

Ghent University and MDxHealth establish new epigenomics center

FDA posts Vibativ advisory committee briefing documents

Cytokinetics reports phase IIa tirasemtiv trial data

Lipid-core peptides may have efficacy as helminth vaccines

Experimental gene therapy approaches for the treatment of drug-resistant epilepsy

Cyclin-dependent kinase 6 as a target in medulloblastoma

Novel murine model of proteinuria developed at Washington University

BioCryst Pharmaceuticals and Presidio Pharmaceuticals end merger

Alimera Sciences develops patient access scheme for Iluvien in U.K.

Boston Scientific commences patient enrollment in EVOLVE II trial of Synergy stent system

Cel-Sci updates on phase III Multikine immunotherapy trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...